Lamotriginum [Latin] en es it fr

Lamotriginum [Latin] Brand names, Lamotriginum [Latin] Analogs

Lamotriginum [Latin] Brand Names Mixture

  • No information avaliable

Lamotriginum [Latin] Chemical_Formula


Lamotriginum [Latin] RX_link

Lamotriginum [Latin] fda sheet

Lamotriginum_[Latin] FDA

Lamotriginum [Latin] msds (material safety sheet)

Lamotriginum_[Latin] MSDS

Lamotriginum [Latin] Synthesis Reference

M. G. Baxter et al., Eur. pat. Appl. 21,121 (1981 to Wellcome Foundation); D. A. Sawyer et al., U.S. pat. 4,602,017 (1986)

Lamotriginum [Latin] Molecular Weight

256.091 g/mol

Lamotriginum [Latin] Melting Point

216-218 oC (uncorr)

Lamotriginum [Latin] H2O Solubility

No information avaliable

Lamotriginum [Latin] State


Lamotriginum [Latin] LogP


Lamotriginum [Latin] Dosage Forms

Tablet; Chewable

Lamotriginum [Latin] Indication

For the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome; For the maintenance treatment of Bipolar I Disorder

Lamotriginum [Latin] Pharmacology

Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine is also used in the treatment of depression and bipolar disorder. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate.

Lamotriginum [Latin] Absorption


Lamotriginum [Latin] side effects and Toxicity

LD50=250 (mg/kg) (in rat, mice); LD50>640 orally (mg/kg) (in rat, mice) (Sawyer); Decreased level of consciousness, coma, delayed heartbeat, increased seizures, lack of coordination, rolling eyeballs

Lamotriginum [Latin] Patient Information

Lamotriginum [Latin] Organisms Affected

Humans and other mammals